Swedish Orphan Biovitrum AB/  SE0000872095  /

OMX Nordic Equities
11/18/2019  5:29:33 PM Chg. - Volume Bid5:29:33 PM Ask5:29:33 PM Market Capitalization Dividend Y. P/E Ratio
157.05SEK - 427,015
Turnover: 66.5 mill.
157.25Bid Size: 3,057 157.45Ask Size: 670 42.33 bill.SEK 0.00% 17.51

Business description

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families.
 

Management board & Supervisory board

CEO
Guido Oelkers
Management board
Henrik Stenqvist, Amy Pott, Anne Marie de Jonge Schuermans, Armin Reininger, Milan Zdravkovic, Norbert Oppitz, Paula Treutiger, Philip Wood, Sofiane Fahmy, Torbjörn Hallberg
Supervisory board
Håkan Björklund, Annette Clancy, Björn Ohlsson, David Allsop, Elisabeth Svanberg, Hans GCP Schikan, Helena Saxon, Katy Mazibuko, Kristin Strandberg, Lennart Johansson, Matthew Gantz, Pia Axelson
 

Company data

Name: Swedish Orphan Biovitrum AB
Address: -,SE-112 76 Stockholm
Phone: +46-8-697-2000
Fax: +46-8-697-2330
E-mail: -
Internet: www.sobi.com/
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 37.74%
IPO date: -

Investor relations

Name: Paula Treutiger
IR phone: +46-73-366-6599
IR Fax: -
IR e-mail: paula.treutiger@sobi.com

Company calendar

CW 7 | 2/13/2020 4th Quarter/Annual Report
 

Main Shareholders

Freefloat
 
37.74%
Investor AB
 
35.87%
BNY Mellon NA (former Mellon)
 
9.27%
Morgan Stanley Smith Baney LLC
 
8.07%
STATE STREET BANK AND TRUST CO
 
4.61%
Swedbank Robur funds
 
4.44%
Others
 
0.00%